Table 2 Therapeutic peptides and their uses
From: Evaluation of the use of therapeutic peptides for cancer treatment
| Peptide name | Validation | Cell lines examineda | Ref. |
|---|---|---|---|
| Antimicrobial peptides | |||
| Magainin II | in vitro | Bladder cancer cells: RT4 pathologic grade 1, 647 V grade 2, and 486P grade 4 | [32] |
| NRC-3 and NRC-7 | In vitro & in vivo | Breast cancer: MDA-MB-231, MDA-MB-468, SKBR3, MCF-7 and paclitaxel resistant MCF-7 (MCF-7-TX400) and murine mammary 4 T1 carcinoma cells | [34] |
| Buforin IIb | In vitro & in vivo | Cervical carcinoma (HeLa), leukaemia (Jurkat cells) and lung cancer (NCI-H460) cells | [37] |
| BR2 | in vitro | Cervical carcinoma (HeLa), colon cancer (HCT116) and murine melanoma (B16-F10) cells | [52] |
| Cell penetrating peptides | |||
| Dox-TAT | in vitro | Breast cancer (MCF-7 and MCF-7/ADR) and rat prostate carcinoma (AT3B1) cells | [53] |
| Tumour targeting peptides | |||
| RGD-SSL-Dox | In vitro & in vivo | Melanoma (A375) and murine (B16-F10) melanoma cells | [61] |
| LPD-PEG-NGR | In vitro & in vivo | Fibrosarcoma (HT-1080) cells | [66] |
| Therapeutic peptides target transduction pathway | |||
| PNC-2 and PNC-7 | in vitro | Pancreatic cancer (MIA-PaCa) cells | [109] |
| Cardiac natriuretic peptides | In vitro & in vivo | Pancreatic cancer (HPAC), renal carcinoma (SW156), breast adenocarcinoma (HCCI428), ovarian adenocarcinoma (NIHOVCAR-3), modularly thyroid carcinoma (TT), glioblastoma (LNZTA3WT4) and lung carcinoma (NCI-H1963) cells | [111–118] |
| RGD-PEG-Suc-PD0325901 | In vitro & in vivo | Glioblastoma (U87MG) cells | [126] |
| VWCS | In vitro | Head and neck squamous cell carcinoma (HNSCC) and oral epidermoid carcinoma (KB) cells | [140] |
| FWCS | In vitro | Head and neck squamous cell carcinoma (HNSCC) and oral epidermoid carcinoma (KB) cells | [141] |
| Therapeutic peptides target cell cycle | |||
| p16 | In vitro | Pancreatic cancer (AsPC-1 and BxPC-3) cells | [166] |
| Bac-7-ELP-p21 | In vitro | Ovarian carcinoma (SKOV-3) cells | [75] |
| Pen-ELP-p21 | In vitro | Cervical carcinoma (HeLa) and ovarian carcinoma (SKOV-3) cells | |
| Therapeutic peptides induce cell death | |||
| TAT-Bim | In vitro & in vivo | Murine T-cell lymphoma (EL4), pancreatic cancer (Panc-02) and melanoma (B16-F10) cells | [193] |
| Poropeptide-Bax | In vitro | Melanoma (SK-MEL-28) cells | [194] |
| R8-Bax | In vitro & in vivo | Cervical carcinoma (HeLa) and murine mammary carcinoma (TS/A) cells | [194] |
| CT20p-NP | In vitro & in vivo | Breast cancer (MCF-7 or MDA-MB-231) and colon cancer (HCT-116) cells | [195] |
| RRM-MV | In vitro | Squamous cell carcinoma (COLO16) and malignant melanoma (MM96L), and murine melanoma (B16-F10) cells | [197, 199] |
| RRM-IL12 | In vitro | Mouse melanoma (B16-F10) cells | [197] |
| Therapeutic peptides target tumour suppressor protein | |||
| PNC-27 | In vitro | Cervical carcinoma (HeLa), colon cancer (SW1417 and H11299), breast cancer (MDA-MB-453 and MCF-7), osteosarcoma (SAOS2), leukaemia (K562), pancreatic cancer (MIA-PaCa-2) and melanoma (A-2058) cells. Rat k-ras-transformed pancreatic cancer (TUC-3) and transformed endothelial (E49) cells | [214, 216, 217] |
| PNC-21 | In vitro | Cervical carcinoma (HeLa), colon cancer (SW1417 and H1299), breast cancer (MDA-MB-453), and osteosarcoma (SAOS2) cells. Rat k-ras-transformed pancreatic cancer (TUC-3) and transformed endothelial (E49) cells | [214] |
| PNC-28 | In vitro & in vivo | Breast cancer (MDA-MB-453), colon cancer (H1299 and SW1417), osteosarcoma (SAOS2), cervical carcinoma (HeLa) and pancreatic cancer (MiaPaCa-2) cells. Rat k-ras-transformed pancreatic cancer (TUC-3) and transformed endothelial (E49) cells | [214, 219, 232] |
| Tat-αHDM2 | In vitro & In vivo | Melanoma (MM-23, MM-24 and MM-26), retinoblastoma (Y79 and WERI), osteosarcoma (U2OS), and cervical carcinoma (C33A) cells | [220] |
| Therapeutic peptides target transcription factors | |||
| Int-H1-S6A, F8A | In vitro | Breast cancer (MCF-7) cells | [230] |
| Pen-ELP-H1 | In vitro | Breast cancer (MCF-7) cells | [76] |
| BACl-ELP-H1 | In vivo | Glioma (U-87 MG and D54) and murine glioma (C6) cells | [231] |